期刊文献+

围绝经期及绝经5年内和大于5年妇女对雌激素替代治疗的反应:腰椎及髋部骨密度变化 被引量:1

Reaction to hormone replacement therapy in women at peirmenopausal period and within and more than 5 years postmenopause:changes of bone mineral density at lumbar spine and hip
下载PDF
导出
摘要 目的:探讨围绝经期及绝经5年内和>5年的妇女应用激素替代治疗对腰椎及髋部骨密度的变化的影响。方法:实验于2003-05/2004-05在沈阳医学院奉天医院完成。从妇科普查参检的围绝经及绝经后5年内及>5年的妇女中抽出90例骨质疏松妇女。参加实验的妇女均无心血管病史,无心、肝、肾、乳腺及生殖器肿瘤等器质性病变,且知情同意,受试前至少6个月未使用过性激素及影响骨代谢的药物。按不同绝经年限分为3组,均口服7-甲基异炔诺酮和钙剂治疗6个月。3组妇女比较治疗前后第2~4腰椎及髋部骨密度的变化情况。结果:按意向性处理分析,90例患者进入结果分析。①围绝经期妇女组治疗前及治疗后髋部骨密度分别为(0.631±0.098)和(0.842±0.076)g/cm2,腰椎骨密度分别为(0.806±0.128)和(0.898±0.106)g/cm2,治疗后骨密度的增加有统计学意义(t=3.032,P<0.01;t=2.319,P<0.05)。②绝经5年以上妇女组治疗前及治疗后髋部骨密度分别为(0.625±0.090)和(0.703±0.108)g/cm2,腰椎骨密度分别为(0.783±0.118)和(0.866±0.127)g/cm2,治疗后骨密度增加,差异有显著性意义(t=3.036,P<0.01;t=2.622,P<0.05)。③绝经5年之内妇女组治疗前及治疗后髋部骨密度分别为(0.627±0.082)和(0.656±0.095)g/cm2,腰椎骨密度分别为(0.798±0.106)和(0.812±0.103)g/cm2,在治疗后骨密度的增加无明显差别(分别t=1.266,1.622,P>0.05)。结论:激素替代疗法对围绝经期及绝经5年以上的骨质疏松妇女主要起治疗作用,对于绝经后5年内的妇女,仅减缓骨丢失。 AIM:To investigate the effect of hormone replacement therapy on the changes of bone mineral density at lumbar spine and hip in women at peirmenopausal period and within and more than 5 years postmenopause.METHODS:The experiment was carried out in Fengtian Hospital of Shenyang Medical College from May 2003 to May 2004.Ninety peirmenopausal and postmenopausal women with osteoporosis, who received general gynaecological examination, were selected.All the subjects had no history of cardiovascular disease,no organic lesions of heart,liver,kidney,mammary gland and genital tumor,they all took part in the study voluntarily,they had not taken any gonadal hormone or the drugs that could affect the bone metabolism within at least 6 months before the test.All the subjects were divided into 3 groups according to the postmenopausal years, they were treated with oral livial and Caltrate D for 6 months.The changes of bone mineral density at lumbar 2- 4 and hip before and after treatment were compared among the 3 groups.RESULTS:According to intention to treat analysis,all the 90 cases were involved in the analysis of results.① In the perimenopausal group,the bone mineral densities before and after treatment at hip were(0.631± 0.098) and(0.842± 0.076) g/cm2,respectively,and those at lumbar 2- 4 were(0.806± 0.128) and(0.898± 0.106) g/cm2,the bone mineral densities were significantly increased after treatment(t=3.032,P< 0.01;t=2.319,P< 0.05).② In the more than 5 years postmenopause group,the bone mineral densities before and after treatment at hip were(0.625± 0.090) and(0.703± 0.108)g/cm2,and those at lumbar 2- 4 were(0.783± 0.118) and(0.866± 0.127)g/cm2,the bone mineral densities were significantly increased after treatment(t=3.036,P< 0.01;t=2.622,P< 0.05).③ In the within 5 years postmenopause group,the bone mineral densities before and after treatment at hip were(0.627± 0.082) and (0.656± 0.095) g/cm2,and those at lumbar 2- 4 were(0.798± 0.106) and(0.812± 0.103)g/cm2,the bone mineral densities were insignificantly increased after treatment(t =1.266,1.622,P >0.05).CONCLUSION:The hormone replacement therapy has curative effects mainly on women at peirmenopausal period and more than 5 years postmenopause,and it can only relieve the loss of bone mass in women within 5 years postmenopause.
作者 周晔 周姝
出处 《中国临床康复》 CSCD 北大核心 2005年第19期168-169,共2页 Chinese Journal of Clinical Rehabilitation
  • 相关文献

参考文献6

  • 1郝新平.我国骨质疏松症研究水平亟待提高.中国医学论坛报,2001,27(23):2-2.
  • 2张丽萍.植物雌激素对绝经后骨质疏松的影响[J].中国临床康复,2003,7(18):2589-2589. 被引量:11
  • 3Moore RA, Livial: a review of clinical studies. Br J Obstet Gynaecol 1999; 106 Suppl 19:1-21.
  • 4Volker W, Coelingh Bennink HJ, Helmond FA. Effects of tibolone on the endometrium. Climacteric 2001;4(3):203-8.
  • 5Conner P, Christow A, Kersemaekers W, et al. A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolon and continuous combined estrogen-progestogen treatment. Climacteric 2004;7(1):50-8.
  • 6Gallagher JC, Baylink DJ,Freeman R, et al. Prevention of loss with tibolone in post menopausal women: results of two randomized, double-blind, placebo-controlled, doze-finding studies. J Clin Endocrinol Metab 2001;86:4717-26.

二级参考文献12

  • 1Domstauder E, Jisa E, Unlerrider I, et al. Estrogenic activity of two standardized red clover extracts(menoflavon) intended for large scale use in hormone replacement therapy. Steroid Biochem Mol Biol 2001:78:67 -75.
  • 2Arjmandi BH, Alekel, Hojjis BW, et al. Dietary soybean protein prevent bone joss in an ovariectomijed rat modej of osteoporosis. J Nutr 1996:126(1 ): 161.
  • 3Arjmandi BH, Biruhaum R, Goyaj NV, et al. Bone sparing effect of soy protein in ovarian hormone deficient rats is related to its isoflavone contem. Am J Clin Nutr 1998; 68 (6s): 1358.
  • 4Fanti P, Monier Faugere MC, Geng Z, et al. The Phytoestrogen genistein reduces bone loss in short term ovariectomized rats. Osteoporos Int 1998; 8(3): 274.
  • 5Blair HC, Jordan SE, Peterson TG, et al. Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovanectomized rats. J Cell Biochem 1996:61(4): 629.
  • 6Tsutsumi N. Ettect of coumestrol on bone metabolism in organ culture. Biol Pharm Bulllll 1995: 18(7): 1012.
  • 7Draper CR, Edej M J, Dick IM. J Phytoestrogens reduce bone resorption in oophorectomized rats. JNUTR 1997: 127(9): 1795.
  • 8Cheng SL,Zhang SF, Nelson TL, et al. Stimulation of humanostcoblast differention and function by lpriflavone and its metbolites. Calcif Trssue Int 1994:55 (5):356.
  • 9Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the Ligand binding specificity band transcript tissue distyibution of estyogen alpha and bete. Endocrinology 1997; 138(3): 863.
  • 10Setchell KD, Borriello SP, Hulme P, et al. Nonesteroidal estrogens of dietary origin:possible roles in hormone-dependent disease. Am J Clin Nutr 1984; 40:569 578.

共引文献13

同被引文献9

  • 1许良智,庄静,乔林.绝经后骨质疏松性骨折的危险因素及预防[J].实用妇产科杂志,2006,22(7):391-393. 被引量:9
  • 2杨式之,赵霞.更年期妇女性激素与失骨关系的探讨[J]华西医科大学学报,1988(02).
  • 3Gayatri Gupta,Wilbert S. Aronow. Treatment of Postmenopausal Osteoporosis[J] 2007,Comprehensive Therapy(3):114~119
  • 4Sarah L. Morgan,Debbie C. Strong,Elizabeth M. Kitchin,Kelley E. Johnston,Robert A. DiSilvestro,Tsunenobu Tamura. Zinc status of women with low bone mineral density who receive calcium supplements[J] 2006,Biological Trace Element Research(3):211~222
  • 5Anne M. Kenny,Karen M. Prestwood,Bradley Biskup,Bertha Robbins,Enid Zayas,Alison Kleppinger,Joseph A. Burleson,Lawrence G. Raisz. Comparison of the effects of calcium loading with calcium citrate or calcium carbonate on bone turnover in postmenopausal women[J] 2004,Osteoporosis International(4):290~294
  • 6S. Domrongkitchaiporn,B. Ongphiphadhanakul,W. Stitchantrakul,N. Piaseu,S. Chansirikarn,G. Puavilai,R. Rajatanavin. Risk of Calcium Oxalate Nephrolithiasis after Calcium or Combined Calcium and Calcitriol Supplementation in Postmenopausal Women[J] 2000,Osteoporosis International(6):486~492
  • 7A. Gürlek,M. Bayraktar,O. Gedik. Comparison of Calcitriol Treatment with Etidronate–Calcitriol and Calcitonin–Calcitriol Combinations in Turkish Women with Postmenopausal Osteoporosis: A Prospective Study[J] 1997,Calcified Tissue International(1):39~43
  • 8H. Rico,M. Revilla,E. R. Hernández,L. F. Villa,M. Alvarez Buergo. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: A prospective study[J] 1995,Calcified Tissue International(3):181~185
  • 9谭世桥,唐晓红.钙剂在绝经后骨质疏松症防治中的作用[J].中国临床康复,2004,8(3):541-541. 被引量:12

引证文献1

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部